Top Story

NIH selects five Lasker Clinical Research Scholars

November 16, 2019

Ixazomib extends PFS as first-line maintenance for certain patients with multiple myeloma

November 7, 2019
A randomized phase 3 trial designed to evaluate ixazomib as first-line maintenance therapy for adults with myeloma who did not undergo stem cell transplantation met its…
FDA News

FDA restructures, renames office that reviews cancer therapies

November 6, 2019
The FDA office that reviews applications for cancer therapies has been renamed and reorganized. The Center for Drug Evaluation and Research’s Office of Oncologic…
In the Journals

Higher provider patient volume linked to better myeloma outcomes

November 1, 2019
Patients with multiple myeloma achieved better outcomes if they received care from providers who had more experience treating the disease, according to results of a…
More Headlines »

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »

VIDEO: Novel testing approaches better equip physicians to identify myeloma risks

July 16, 2016
More »
Resource Centers
At Issue: Multiple Myeloma Resource Center

At Issue: Multiple Myeloma Resource Center